Laura R
☆    

Israel,
2020-03-22 09:58
(1656 d 10:26 ago)

Posting: # 21294
Views: 4,452
 

 Impact of COVID-19 on HV trials [Study Per­for­mance]

Hi, was wondering how P1 CROs are dealing with the COVID19 crisis, and if there is any chance to keep studies moving (in small cohorts, no overnight stays, etc).
Should HV studies considered an essential activity per the new FDA/EMA guidances, is voluteering in a Phase 1 study considered a valid reason to be outside? Laura
Ohlbe
★★★

France,
2020-03-23 00:38
(1655 d 19:46 ago)

@ Laura R
Posting: # 21295
Views: 3,337
 

 Impact of COVID-19 on HV trials

Dear Laura,

❝ Hi, was wondering how P1 CROs are dealing with the COVID19 crisis, and if there is any chance to keep studies moving (in small cohorts, no overnight stays, etc).


It certainly depends on national and local recommendations, but I would say that the probability to run a study till its end in good conditions is getting increasingly close to nil, unless maybe each subject is only expected to come once. Restrictions increase almost daily. You would have a high risk that your subjects start the study but are unable to return to the site for the next period or even the next day.

More than that: in the EU and in an increasing number of countries, I'm not sure anybody can be considered healthy. A healthy volunteer is a guy who does not know yet that he's sick. Unless you quarantine all subjects and all staff members for a fortnight, and keep your fingers crossed that none of them develops any symptoms.

❝ Should HV studies considered an essential activity per the new FDA/EMA guidances, is voluteering in a Phase 1 study considered a valid reason to be outside?


Being a healthy volunteer is not a profession, so I would not tick the "professional reason" box. I think the only exception authorities would be ready to grant is for a study on an new COVID-19 drug or vaccine.

We all have to be reasonable. The more disciplined we are staying at home, the more efficient the measure will be and the shorter it will be. Stay safe. Stay at home. Even if you loose a few months of your drug development. We should take this opportunity to revise our SOPs and do all these things we never have the time to do (or don't want to do because it's a pain). But from home.

Regards
Ohlbe
Laura R
☆    

Israel,
2020-03-25 10:51
(1653 d 09:33 ago)

@ Ohlbe
Posting: # 21299
Views: 2,832
 

 Impact of COVID-19 on HV trials

Thanks Ohlbe, indeed from my inquiries this is the direction everyone is taking..
It will be interesting to see what measures will be implemented in stud(ies) conduct after the "acute" phase of this pandemic is over.
kratos
☆    

India,
2020-03-31 05:09
(1647 d 16:16 ago)

@ Laura R
Posting: # 21308
Views: 2,665
 

 Impact of COVID-19 on HV trials

Hi, certainly many many studies are impacted by the COVID situation.
Not the best time to initiate a new study; But does anyone have an experience where a trial had to be aborted half way ?
We completed Period 1 of a study in an Indian CRO and during the washout, the government issued a lock down, so period 2 is postponed until everything gets back to 'normalcy'.
My question here is, in case we have partial replicate study, and such a situation came up after completion of two periods, will it be acceptable to increase the washout for just the final period ? considering between period 1 and 2 we would have had a shorter washout, will this inconsistency be acceptable ?
Thanks
UA Flag
Activity
 Admin contact
23,240 posts in 4,884 threads, 1,655 registered users;
66 visitors (0 registered, 66 guests [including 9 identified bots]).
Forum time: 21:25 CEST (Europe/Vienna)

The epistemological value of probability theory is based on the fact
that chance phenomena, considered collectively and on a grand scale,
create non-random regularity.    Andrey Kolmogorov

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5